STAT+: Pharmalittle: Pharma showers cash on a rising U.S. Senate star; FDA restricts use of a Glaxo Covid treatment

U.S. Sen. Tim Scott of South Carolina, a rising star in the Republican Party, is getting showered with pharmaceutical industry money before facing voters this fall.

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of meetings, online calls, and deadlines has predictably returned. But what can you do? The world, such as it is, keeps spinning. So time to fire up the neurons with a cup or three of stimulation, especially given the frosty temperature outside. Our choice today is glazed doughnut. Feel free to join us. Meanwhile, here is the latest menu of tidbits to help you on your way. Hope all goes well and you have a meaningful day. …

U.S. Sen. Tim Scott, a rising star in the Republican Party with broad popularity in his home state of South Carolina, is getting showered with pharmaceutical industry money before facing voters this fall, Kaiser Health News says. Scott was the top recipient of pharma campaign cash in Congress during the second half of 2021, receiving $99,000, emerging as a new industry favorite. Though Scott has been a perennial recipient since arriving in Congress in 2011, the latest amount is nearly twice his previous highest haul. The state’s junior senator is widely viewed as destined for greater things during his political career. And this is an existential moment for pharma, when securing allies is critical.

Continue to STAT+ to read the full story…